Abstract: Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.

Abstract: The invention described herein relates to oral dosage form therapies for treating metabolic disorders using combinations of inhibitors of SGLT1 and SGLT2. In such dosage forms, SGLT1 is effective in the intestinal lumen, and is either not absorbed, or poorly absorbed, while the SGLT2 inhibitor inhibits sugar reabsorption in the kidney by inhibiting SGLT2 activity. Metabolic disorders treated by combined SGLT1 and SGLT2 oral dosage forms include disorders associated with abnormal accumulation of liver lipids, which may also be copresent with hyperglycemia.

Abstract: Disclosed herein are methods, sodium-dependent glucose transporter (SGLT)1 compounds and compositions for the treatment of postprandial hypoglycemia, postprandial hypoglycemia that occurs as a consequence of gastric surgery.

Abstract: A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

Abstract: The present invention discloses novel methods and omental, myocardial, liver, lung, renal, peritoneal, intestinal and pancreatic mesothelial cells which are useful for a number of procedures including drug discovery, co-culturing, cell therapy and bioassay. The invention provides a method for isolating these cells that improves upon the methods previously used and provides cells isolated in quantity. The present invention provides a list of secreted proteins from omentum mesothelial cells that can be utilized in the described cell based assays.

Abstract: A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X7 mRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

Abstract: The invention provides cells, compositions and methods based on the use of stromal cells to support the proliferation of undifferentiated embryonic or adult stem cells in vitro. The stem cells produced in the method are useful in providing a source of uncommitted or differentiated and functional cells for research, transplantation and development of tissue engineered products for the treatment of human diseases and traumatic tissue injury repair in any tissue or organ site within the body.

Abstract: The invention provides compositions and methods for the use of adipose tissue-derived stromal cells for the treatment and repair of any ocular-associated tissue defect, including but not limited to those secondary to trauma, metabolic disease, inborn errors, or surgery. The adipose tissue-derived stromal cells are cultured in the undifferentiated, differentiated or adipocyte state either alone or in the presence of a biocompatible material. The resulting materials are employed surgically to correct a variety of correct intra-ocular defects.

Abstract: The invention provides cells, compositions and methods based on the differentiation of adipose tissue-derived stromal cells into a cell expressing at least one genotypic or phenotypic characteristic of a pancreas cell. The cells produced in the method are useful in providing a source of differentiated and functional cells for research, implantation, transplantation and development of tissue engineered products for the treatment of diseases of the pancreas and pancreatic tissue repair.